Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Takahashi T. Overall survival is the primary endpoint in a trial of neoadjuvant chemotherapy for bladder cancer? Cancer 2019;125:4105-4106. [PMID: 31355910 DOI: 10.1002/cncr.32415] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]

For:	Takahashi T. Overall survival is the primary endpoint in a trial of neoadjuvant chemotherapy for bladder cancer? Cancer 2019;125:4105-4106. [PMID: 31355910 DOI: 10.1002/cncr.32415] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]

Number

Cited by Other Article(s)

Takahashi T. Comments on "Survival after Neoadjuvant/Induction Combination Immunotherapy versus Combination Platinum-based Chemotherapy for Locally Advanced (Stage III) Urothelial Cancer.". Int J Cancer 2022;151:1847-1848. [PMID: 35815951 DOI: 10.1002/ijc.34206] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2022] [Accepted: 06/21/2022] [Indexed: 11/08/2022]

Re: Ekaterina Laukhtina, Shahrokh F. Shariat. Phase II Study of Gemcitabine and Split-dose Cisplatin plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients with Muscle-invasive Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.04.010. Eur Urol 2022;82:e107-e108. [PMID: 35787938 DOI: 10.1016/j.eururo.2022.06.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2022] [Accepted: 06/10/2022] [Indexed: 11/21/2022]